A photo of Robin Norris.

Director, Clinical Research for Oncology, Division of Oncology

Co-Director, Young Adult Oncology Program, Division of Oncology

Associate Professor, UC Department of Pediatrics

513-517-2067

Board Certified

My Biography & Research

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Leukemia, Young Adult Cancer

Research Divisions

Cancer and Blood Diseases, Oncology

My Locations

My Education

BA: Human Biology, Stanford University, Stanford, CA, 1997.

MD: University of Pennsylvania School of Medicine, Philadelphia, PA, 2001.

MPH: Epidemiology, University of California, Berkeley, CA, 2005.

MS: Translational Research, University of Pennsylvania School of Medicine, Institute for Translational Medicine and Therapeutics, Philadelphia, PA, 2010.

Intern: Pediatrics, University of California, San Francisco, CA, 2001-2002.

Resident: Pediatrics, University of California, San Francisco, CA, 2002-2004.

Fellow: Pediatric Hematology/Oncology, The Children’s Hospital of Philadelphia, Philadelphia, CA, 2005-2008.

My Publications

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Burke, GA A; Beishuizen, A; Bhojwani, D; Burkhardt, B; Minard-Colin, V; Norris, RE; Kabickova, E; Pinarli, FG; Tacyildiz, N; Howes, A; et al. Leukemia. 2020; 34:2271-2275.

Location of Death and End-of-Life Characteristics of Young Adults with Cancer Treated at a Pediatric Hospital. Mark, MS J; Yang, G; Ding, L; Norris, RE; Thienprayoon, R. Journal of Adolescent and Young Adult Oncology. 2019; 8:417-422.

Pediatric acute lymphoblastic leukemia presenting with periorbital edema. Stein, AP; Norris, RE; Shah, JR. Otolaryngology Case Reports. 2018; 9:11-14.

Collaborating with Adolescents and Young Adults with Cancer as Advisors. McGrady, ME; Norris, RE; Pai, AL H. Journal of Adolescent and Young Adult Oncology. 2018; 7:499-503.

Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Norris, RE; Fox, E; Reid, JM; Ralya, A; Liu, XW; Minard, C; Weigel, BJ. Pediatric Blood and Cancer. 2018; 65:e26944-e26944.

Evaluating the role of phase I expansion cohorts in oncologic drug development. Norris, RE; Behtaj, M; Fu, P; Dowlati, A. Investigational New Drugs. 2017; 35:108-114.

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Gupta, N; Hanley, MJ; Venkatakrishnan, K; Perez, R; Norris, RE; Nemunaitis, J; Yang, H; Qian, MG; Falchook, G; Labotka, R; et al. British Journal of Clinical Pharmacology. 2016; 82:728-738.